GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lirum Therapeutics Inc (NAS:LRTX) » Definitions » Beginning Cash Position

Lirum Therapeutics (Lirum Therapeutics) Beginning Cash Position : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2024. Start your Free Trial

What is Lirum Therapeutics Beginning Cash Position?

Lirum Therapeutics's Beginning Cash Position for the quarter that ended in Dec. 2023 was $0.00 Mil.

Lirum Therapeutics's quarterly Beginning Cash Position declined from Dec. 2022 ($0.07 Mil) to Sep. 2023 ($0.00 Mil) but then stayed the same from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($0.00 Mil).

Lirum Therapeutics's annual Beginning Cash Position stayed the same from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) but then increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.17 Mil).


Lirum Therapeutics Beginning Cash Position Historical Data

The historical data trend for Lirum Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lirum Therapeutics Beginning Cash Position Chart

Lirum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Beginning Cash Position
- - 0.17

Lirum Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Sep23 Dec23
Beginning Cash Position - - 0.07 - -

Lirum Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.


Lirum Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Lirum Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


Lirum Therapeutics (Lirum Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
590 Madison Avenue, 21st Floor, New York, NY, USA, 10022
Lirum Therapeutics Inc is clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development, and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways, and commercial opportunities. Its product candidate, LX-101, formerly 765IGF-MTX, is a novel, clinical-stage, "next generation," precision-engineered targeted therapy directed to the IGF-1R.

Lirum Therapeutics (Lirum Therapeutics) Headlines

No Headlines